U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Source link
Trending
- Sheamus names former WWE champion as someone he wanted to work with
- Trilateral critical mineral deals, wider air pact key to India-UAE ties ahead, says UAE Minister
- Protium in advanced talks to buy Clix Capital; Rs 1,900-2,200 crore valuation likely
- As monsoon revives, ‘intense’ rain likely to hit over 10 states | India News
- Nickelodeon actress opens residual checks worth pennies on social media
- Today’s Minute Cryptic Answer and Hints for July 27, 2026
- KFC operator Devyani International bets on tech, portfolio boost as demand picks up pace again
- Germany's liberal party leader Kubicki on Berlin Pride attack: 'Islamism is the Enemy'
